Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rivastigmine tartrate
Drug ID BADD_D01956
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status Prescription; Discontinued
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D02558
MeSH ID D000068836
PubChem ID 6918078
TTD Drug ID D0WY5Q
NDC Product Code 60687-574; 55111-355; 62756-146; 62756-148; 62756-145; 75834-135; 51991-794; 33342-090; 49706-1826; 65862-650; 51991-795; 71209-012; 71209-015; 0904-6587; 62704-0122; 33342-092; 65862-651; 46708-066; 75834-134; 55111-354; 50379-0012; 33342-089; 46708-873; 71209-014; 65862-649; 65862-648; 62756-147; 0904-7107; 62756-136; 65372-1152; 55111-352; 55111-066; 71209-013; 55111-353; 65862-612; 75834-136; 72241-011; 33342-091; 53104-7571; 46708-064; 72241-013; 51991-796; 72241-012; 75834-133; 51991-793; 72241-014; 46708-065; 70518-3012; 46708-063
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C18H28N2O8
CAS Registry Number 129101-54-8
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C.C(C(C(=O)O)O)(C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AstheniaCholinesteraseP06276T99799Not Available
DiarrhoeaCholinesteraseP06276T99799Not Available
DizzinessCholinesteraseP06276T99799Not Available
VomitingCholinesteraseP06276T99799Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bursitis15.04.01.001--Not Available
Cachexia08.01.01.009; 16.32.03.011; 14.03.02.001--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
Cardiovascular disorder24.03.02.009; 02.01.01.001--Not Available
Cataract06.06.01.001--
Cellulitis23.09.01.001; 11.02.01.001--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Cerebrovascular disorder24.03.05.002; 17.08.02.002--Not Available
Chest pain02.02.02.011; 22.02.08.003; 08.01.08.002--Not Available
Chills15.05.03.016; 08.01.09.001--
Cholecystitis09.03.01.001--
Cholelithiasis09.03.01.002--Not Available
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Coagulopathy01.01.02.001--Not Available
Cogwheel rigidity17.01.05.001; 15.05.04.006--Not Available
Cold sweat23.02.03.002; 08.01.03.024--Not Available
Colitis07.08.01.001--
Collagen disorder15.06.01.005; 10.04.04.002--Not Available
Colon cancer07.21.01.001; 16.13.01.001--Not Available
Coma17.02.09.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctival haemorrhage24.07.05.001; 06.07.01.001--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Coordination abnormal17.02.02.004--Not Available
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Cough22.02.03.001--
Cystitis20.03.02.002; 11.01.14.001--
Deafness04.02.01.001--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 15 Pages